Symbols / INSM Stock $97.85 +1.17% Insmed Incorporated

Healthcare • Biotechnology • United States • NMS
INSM (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. William H. Lewis J.D., M.B.A.
Exch · Country NMS · United States
Market Cap 21.21B
Enterprise Value 20.73B
Income -1.18B
Sales 819.56M
FCF (ttm) -606.20M
Book/sh 3.25
Cash/sh 5.64
Employees 1,664
Insider 10d —
IPO Jun 01, 2000
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 301.33
PEG 1.09
P/S 25.88
P/B 30.06
P/C —
EV/EBITDA -21.84
EV/Sales 25.29
Quick Ratio 3.88
Current Ratio 4.47
Debt/Eq 105.34
LT Debt/Eq —
EPS (ttm) -5.76
EPS next Y 0.32
EPS Growth —
Revenue Growth 229.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA -31.11%
ROE -294.46%
ROIC —
Gross Margin 81.81%
Oper. Margin -65.46%
Profit Margin -144.44%
Shs Outstand 216.75M
Shs Float 198.30M
Insider Own 0.52%
Instit Own 105.65%
Short Float 9.95%
Short Ratio 4.67
Short Interest 19.13M
52W High 212.75
vs 52W High -54.01%
52W Low 90.39
vs 52W Low 8.25%
Beta 0.77
Impl. Vol. 61.26%
Rel Volume 1.40
Avg Volume 3.24M
Volume 4.52M
Target (mean) $197.62
Tgt Median $202.00
Tgt Low $140.00
Tgt High $243.00
# Analysts 21
Recom Strong_buy
Prev Close $96.72
Price $97.85
Change 1.17%
About

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$197.62
Mean price target
2. Current target
$97.85
Latest analyst target
3. DCF / Fair value
$-50.34
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$97.85
Low
$140.00
High
$243.00
Mean
$197.62

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-06-08 main JP Morgan Overweight → Overweight $179
2026-06-05 main RBC Capital Outperform → Outperform $195
2026-05-14 main Truist Securities Buy → Buy $185
2026-05-08 main RBC Capital Outperform → Outperform $205
2026-05-08 main Wells Fargo Overweight → Overweight $160
2026-05-08 main Guggenheim Buy → Buy $226
2026-04-17 reit Roth Capital Buy → Buy $212
2026-04-14 main RBC Capital Outperform → Outperform $216
2026-04-01 main Barclays Overweight → Overweight $237
2026-03-30 up Morgan Stanley Equal-Weight → Overweight $212
2026-03-26 main HC Wainwright & Co. Buy → Buy $245
2026-03-25 main Mizuho Outperform → Outperform $206
2026-03-24 main Leerink Partners Outperform → Outperform $215
2026-03-24 main Stifel Buy → Buy $208
2026-03-24 main Wells Fargo Overweight → Overweight $177
2026-03-24 main B of A Securities Buy → Buy $213
2026-03-23 main Wells Fargo Overweight → Overweight $175
2026-02-24 main Mizuho Outperform → Outperform $204
2026-02-23 reit HC Wainwright & Co. Buy → Buy $230
2026-02-20 main Wells Fargo Overweight → Overweight $208
News
RSS: Latest INSM news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-08 LEWIS WILLIAM H Chief Executive Officer — 6,515 $94.03 $612,605
2026-06-05 FLAMMER MARTINA Officer — 4,424 $102.27 $455,248
2026-06-03 BONSTEIN SARA M Chief Financial Officer — 2,404 $102.27 $245,857
2026-06-03 LEWIS WILLIAM H Chief Executive Officer — 7,605 $102.27 $777,763
2026-06-03 SMITH MICHAEL ALEXANDER Officer — 2,159 $102.27 $220,801
2026-06-03 ADSETT ROGER Chief Operating Officer — 2,370 $102.27 $242,380
2026-05-22 SMITH MICHAEL ALEXANDER Officer — 6,149 $108.47 $666,982
2026-05-18 LEWIS WILLIAM H Chief Executive Officer — 10,699 $17.16 $266,840
2026-05-18 LEWIS WILLIAM H Chief Executive Officer — 25,564 $105.32 $2,718,224
2026-05-14 FLAMMER MARTINA Officer — 18,333 $112.76 $2,128,892
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
606.42
+66.73%
363.71
+19.17%
305.21
+24.39%
245.36
Operating Revenue
606.42
+66.73%
363.71
+19.17%
305.21
+24.39%
245.36
Cost Of Revenue
122.94
+43.38%
85.74
+30.76%
65.57
+18.95%
55.13
Reconciled Cost Of Revenue
112.49
+41.00%
79.78
+32.87%
60.05
+20.46%
49.85
Gross Profit
483.49
+73.94%
277.96
+16.00%
239.63
+25.97%
190.23
Operating Expense
1,478.26
+38.86%
1,064.54
+15.64%
920.56
+37.74%
668.36
Research And Development
771.09
+28.87%
598.37
+4.79%
571.01
+43.64%
397.52
Selling General And Administration
701.17
+52.06%
461.12
+33.85%
344.50
+29.62%
265.78
General And Administrative Expense
701.17
+52.06%
461.12
+33.85%
344.50
+29.62%
265.78
Salaries And Wages
331.16
+52.15%
217.66
+38.79%
156.82
+26.45%
124.02
Other Gand A
370.00
+51.98%
243.46
+29.72%
187.68
+32.38%
141.77
Total Expenses
1,601.20
+39.20%
1,150.28
+16.64%
986.14
+36.30%
723.48
Operating Income
-994.78
-26.47%
-786.57
-15.51%
-680.93
-42.42%
-478.12
Total Operating Income As Reported
-1,246.77
-41.96%
-878.25
-23.76%
-709.63
-55.17%
-457.32
EBITDA
-1,177.72
-43.84%
-818.79
-24.03%
-660.18
-47.57%
-447.37
Normalized EBITDA
-986.38
-26.43%
-780.18
-15.77%
-673.93
-41.07%
-477.72
Reconciled Depreciation
16.45
+49.37%
11.01
+4.10%
10.58
+2.40%
10.33
EBIT
-1,194.17
-43.91%
-829.81
-23.71%
-670.76
-46.55%
-457.70
Total Unusual Items
-191.34
-395.55%
-38.61
-380.71%
13.76
-54.69%
30.36
Total Unusual Items Excluding Goodwill
-191.34
-395.55%
-38.61
-380.71%
13.76
-54.69%
30.36
Special Income Charges
-251.99
-174.86%
-91.68
-219.48%
-28.70
-237.95%
20.80
Other Special Charges
—
—
—
—
Restructuring And Mergern Acquisition
251.99
+174.86%
91.68
+219.48%
28.70
+237.95%
-20.80
Net Income
-1,276.78
-39.73%
-913.77
-21.91%
-749.57
-55.66%
-481.53
Pretax Income
-1,271.75
-39.74%
-910.07
-21.83%
-747.01
-55.58%
-480.15
Net Non Operating Interest Income Expense
-83.80
+1.32%
-84.91
-3.94%
-81.69
-208.91%
-26.45
Interest Expense Non Operating
77.58
-3.34%
80.26
+5.25%
76.26
+239.59%
22.45
Net Interest Income
-83.80
+1.32%
-84.91
-3.94%
-81.69
-208.91%
-26.45
Interest Expense
77.58
-3.34%
80.26
+5.25%
76.26
+239.59%
22.45
Interest Income Non Operating
0.00
-100.00%
2.23
+18.44%
1.88
—
Interest Income
0.00
-100.00%
2.23
+18.44%
1.88
—
Other Income Expense
-193.18
-400.69%
-38.58
-347.15%
15.61
-36.07%
24.42
Other Non Operating Income Expenses
-1.84
-6448.28%
0.03
-98.44%
1.86
+131.25%
-5.94
Gain On Sale Of Security
60.66
+14.29%
53.07
+25.01%
42.45
+344.29%
9.55
Tax Provision
5.03
+35.58%
3.71
+45.09%
2.56
+84.74%
1.38
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
0.00
Tax Effect Of Unusual Items
-40.18
-395.55%
-8.11
-380.71%
2.89
0.00
Net Income Including Noncontrolling Interests
-1,276.78
-39.73%
-913.77
-21.91%
-749.57
-55.66%
-481.53
Net Income From Continuing Operation Net Minority Interest
-1,276.78
-39.73%
-913.77
-21.91%
-749.57
-55.66%
-481.53
Net Income From Continuing And Discontinued Operation
-1,276.78
-39.73%
-913.77
-21.91%
-749.57
-55.66%
-481.53
Net Income Continuous Operations
-1,276.78
-39.73%
-913.77
-21.91%
-749.57
-55.66%
-481.53
Normalized Income
-1,125.62
-27.44%
-883.27
-16.15%
-760.43
-48.55%
-511.89
Net Income Common Stockholders
-1,276.78
-39.73%
-913.77
-21.91%
-749.57
-55.66%
-481.53
Diluted EPS
-6.42
-15.26%
-5.57
-4.31%
-5.34
-36.57%
-3.91
Basic EPS
-6.42
-15.26%
-5.57
-4.31%
-5.34
-36.57%
-3.91
Basic Average Shares
199.01
+21.32%
164.04
+16.81%
140.43
+14.14%
123.03
Diluted Average Shares
199.01
+21.32%
164.04
+16.81%
140.43
+14.14%
123.03
Diluted NI Availto Com Stockholders
-1,276.78
-39.73%
-913.77
-21.91%
-749.57
-55.66%
-481.53
Amortization
6.00
+18.78%
5.05
+0.00%
5.05
-0.02%
5.05
Amortization Of Intangibles Income Statement
6.00
+18.78%
5.05
+0.00%
5.05
-0.02%
5.05
Depreciation Amortization Depletion Income Statement
6.00
+18.78%
5.05
+0.00%
5.05
-0.02%
5.05
Depreciation And Amortization In Income Statement
6.00
+18.78%
5.05
+0.00%
5.05
-0.02%
5.05
Total Other Finance Cost
6.22
-9.70%
6.88
-5.96%
7.32
+83.41%
3.99
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
2,264.56
+11.82%
2,025.23
+52.29%
1,329.84
-19.72%
1,656.43
Current Assets
1,794.21
+10.64%
1,621.66
+74.55%
929.06
-27.04%
1,273.38
Cash And Cash Equivalents
510.44
-8.03%
555.03
+15.06%
482.37
-55.09%
1,074.04
Other Short Term Investments
919.60
+4.64%
878.80
+194.83%
298.07
+301.48%
74.24
Receivables
140.86
+170.82%
52.01
+26.28%
41.19
+38.62%
29.71
Accounts Receivable
140.86
+170.82%
52.01
+26.28%
41.19
+38.62%
29.71
Inventory
132.07
+33.97%
98.58
+18.41%
83.25
+19.06%
69.92
Raw Materials
30.62
+55.59%
19.68
-19.87%
24.56
-9.85%
27.25
Work In Process
41.35
+3.54%
39.93
+19.27%
33.48
+49.07%
22.46
Finished Goods
60.10
+54.24%
38.96
+54.58%
25.21
+24.68%
20.22
Prepaid Assets
—
—
—
—
Other Current Assets
91.24
+144.96%
37.24
+54.04%
24.18
-5.06%
25.47
Total Non Current Assets
470.35
+16.55%
403.57
+0.70%
400.77
+4.63%
383.05
Net PPE
139.21
+20.44%
115.58
+10.73%
104.39
+2.26%
102.08
Gross PPE
199.97
+20.54%
165.89
+11.32%
149.01
+5.29%
141.53
Accumulated Depreciation
-60.76
-20.77%
-50.31
-12.72%
-44.63
-13.14%
-39.45
Properties
0.00
0.00
0.00
0.00
Land And Improvements
1.96
0.00
—
—
Buildings And Improvements
10.44
0.00
—
—
Machinery Furniture Equipment
15.02
+14.83%
13.08
+4.52%
12.52
+6.59%
11.74
Construction In Progress
42.41
-17.05%
51.13
+44.23%
35.45
+20.05%
29.53
Other Properties
76.73
+20.61%
63.62
+0.99%
63.00
-0.31%
63.20
Leases
53.40
+40.31%
38.06
+0.02%
38.05
+2.68%
37.06
Goodwill And Other Intangible Assets
233.76
+20.02%
194.76
-2.53%
199.81
-2.47%
204.87
Goodwill
136.11
+0.00%
136.11
+0.00%
136.11
+0.00%
136.11
Other Intangible Assets
97.65
+66.49%
58.65
-7.93%
63.70
-7.35%
68.76
Investments And Advances
—
—
—
0.00
Other Non Current Assets
97.38
+4.45%
93.23
-3.47%
96.57
+26.90%
76.10
Total Liabilities Net Minority Interest
1,525.58
-12.32%
1,739.85
+4.70%
1,661.76
+5.95%
1,568.48
Current Liabilities
468.87
+57.59%
297.53
+31.87%
225.63
+18.60%
190.24
Payables And Accrued Expenses
344.55
+68.16%
204.90
+28.58%
159.35
+14.33%
139.38
Payables
103.46
+23.85%
83.53
+12.26%
74.41
+29.82%
57.32
Accounts Payable
79.91
+9.41%
73.03
+11.68%
65.39
+29.59%
50.46
Other Payable
23.55
+124.26%
10.50
+16.41%
9.02
+31.52%
6.86
Current Accrued Expenses
241.09
+98.65%
121.36
+42.88%
84.94
+3.51%
82.06
Pensionand Other Post Retirement Benefit Plans Current
111.51
+38.85%
80.31
+64.13%
48.93
+52.72%
32.04
Current Debt And Capital Lease Obligation
12.81
+4.02%
12.32
+15.76%
10.64
+30.96%
8.13
Current Capital Lease Obligation
12.81
+4.02%
12.32
+15.76%
10.64
+30.96%
8.13
Current Deferred Liabilities
—
24.70
+268.66%
6.70
-37.38%
10.70
Total Non Current Liabilities Net Minority Interest
1,056.71
-26.74%
1,442.32
+0.43%
1,436.13
+4.20%
1,378.24
Long Term Debt And Capital Lease Obligation
573.86
-49.51%
1,136.56
-4.76%
1,193.35
+2.02%
1,169.74
Long Term Debt
540.96
-50.97%
1,103.38
-4.49%
1,155.31
+2.67%
1,125.25
Long Term Capital Lease Obligation
32.89
-0.85%
33.18
-12.78%
38.04
-14.50%
44.49
Other Non Current Liabilities
482.85
+57.92%
305.77
+25.94%
242.78
+16.44%
208.50
Stockholders Equity
738.98
+158.95%
285.38
+185.98%
-331.92
-477.40%
87.95
Common Stock Equity
738.98
+158.95%
285.38
+185.98%
-331.92
-477.40%
87.95
Capital Stock
2.14
+19.45%
1.79
+21.22%
1.48
+9.06%
1.36
Common Stock
2.14
+19.45%
1.79
+21.22%
1.48
+9.06%
1.36
Share Issued
214.26
+19.44%
179.38
+21.22%
147.98
+9.09%
135.65
Ordinary Shares Number
214.26
+19.44%
179.38
+21.22%
147.98
+9.09%
135.65
Additional Paid In Capital
6,372.06
+37.16%
4,645.79
+49.22%
3,113.49
+11.90%
2,782.42
Retained Earnings
-5,636.69
-29.28%
-4,359.92
-26.52%
-3,446.14
-27.80%
-2,696.58
Gains Losses Not Affecting Retained Earnings
1.46
+163.83%
-2.29
-207.25%
-0.74
-198.54%
0.76
Other Equity Adjustments
1.46
+163.83%
-2.29
-207.25%
-0.74
-198.54%
0.76
Total Equity Gross Minority Interest
738.98
+158.95%
285.38
+185.98%
-331.92
-477.40%
87.95
Total Capitalization
1,279.94
-7.84%
1,388.76
+68.66%
823.39
-32.13%
1,213.20
Working Capital
1,325.33
+0.09%
1,324.13
+88.24%
703.43
-35.06%
1,083.14
Invested Capital
1,279.94
-7.84%
1,388.76
+68.66%
823.39
-32.13%
1,213.20
Net Debt
30.52
-94.43%
548.35
-18.51%
672.94
+1213.97%
51.21
Capital Lease Obligations
45.71
+0.47%
45.49
-6.54%
48.68
-7.48%
52.62
Net Tangible Assets
505.21
+457.53%
90.62
+117.04%
-531.74
-354.81%
-116.92
Tangible Book Value
505.21
+457.53%
90.62
+117.04%
-531.74
-354.81%
-116.92
Interest Payable
0.00
-100.00%
0.36
-83.49%
2.17
-65.69%
6.34
Investmentin Financial Assets
—
—
—
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-935.01
-36.72%
-683.88
-27.53%
-536.25
-33.91%
-400.44
Cash Flow From Continuing Operating Activities
-935.01
-36.72%
-683.88
-27.53%
-536.25
-33.91%
-400.44
Net Income From Continuing Operations
-1,276.78
-39.73%
-913.77
-21.91%
-749.57
-55.66%
-481.53
Depreciation Amortization Depletion
16.45
+49.37%
11.01
+4.10%
10.58
+2.40%
10.33
Depreciation
10.45
+75.29%
5.96
+7.85%
5.53
+4.72%
5.28
Amortization Cash Flow
6.00
+18.78%
5.05
+0.00%
5.05
-0.02%
5.05
Depreciation And Amortization
16.45
+49.37%
11.01
+4.10%
10.58
+2.40%
10.33
Amortization Of Intangibles
6.00
+18.78%
5.05
+0.00%
5.05
-0.02%
5.05
Other Non Cash Items
291.25
+102.05%
144.14
-18.51%
176.88
+3454.03%
4.98
Stock Based Compensation
152.71
+57.70%
96.83
+29.50%
74.78
+29.63%
57.69
Operating Gains Losses
—
0.24
+173.75%
-0.32
-120.97%
1.53
Gain Loss On Investment Securities
—
0.24
+173.75%
-0.32
-120.97%
1.53
Change In Working Capital
-80.30
-2427.51%
-3.18
+91.90%
-39.22
-696.47%
6.58
Change In Receivables
-88.31
-582.86%
-12.93
-8.10%
-11.96
-86.25%
-6.42
Changes In Account Receivables
-88.31
-582.86%
-12.93
-8.10%
-11.96
-86.25%
-6.42
Change In Inventory
-31.52
-84.93%
-17.04
-25.20%
-13.61
-694.22%
-1.71
Change In Prepaid Assets
-53.43
-276.75%
-14.18
-726.14%
2.27
-10.40%
2.53
Change In Payables And Accrued Expense
100.07
+124.42%
44.59
+194.24%
15.15
-69.70%
50.01
Change In Payable
—
—
—
—
Change In Account Payable
—
—
—
—
Change In Other Working Capital
—
—
—
—
Change In Other Current Assets
-2.12
-125.47%
8.34
+141.52%
-20.07
+20.48%
-25.24
Change In Other Current Liabilities
-4.99
+58.21%
-11.95
-8.72%
-10.99
+12.68%
-12.58
Investing Cash Flow
-64.58
+88.93%
-583.17
-160.81%
-223.60
-546.55%
-34.58
Cash Flow From Continuing Investing Activities
-64.58
+88.93%
-583.17
-160.81%
-223.60
-546.55%
-34.58
Net PPE Purchase And Sale
-32.56
-48.52%
-21.92
-64.98%
-13.29
-34.52%
-9.88
Purchase Of PPE
-32.56
-48.52%
-21.92
-64.98%
-13.29
-34.52%
-9.88
Capital Expenditure
-32.56
-48.52%
-21.92
-64.98%
-13.29
-34.52%
-9.88
Net Investment Purchase And Sale
-2.01
+99.64%
-561.25
-162.59%
-213.73
-765.11%
-24.71
Purchase Of Investment
-2,092.01
-32.64%
-1,577.25
-167.91%
-588.73
-490.47%
-99.71
Sale Of Investment
2,090.00
+105.71%
1,016.00
+170.93%
375.00
+400.00%
75.00
Net Business Purchase And Sale
—
—
0.00
0.00
Purchase Of Business
—
—
0.00
0.00
Gain Loss On Sale Of Business
—
—
76.48
0.00
Net Intangibles Purchase And Sale
—
—
—
0.00
Purchase Of Intangibles
—
—
—
0.00
Net Other Investing Changes
-30.00
—
3.42
—
Financing Cash Flow
954.07
-28.85%
1,341.02
+696.15%
168.44
-78.77%
793.27
Cash Flow From Continuing Financing Activities
954.07
-28.85%
1,341.02
+696.15%
168.44
-78.77%
793.27
Net Issuance Payments Of Debt
-4.93
-103.34%
147.39
+12210.93%
-1.22
-100.35%
349.40
Issuance Of Debt
0.00
-100.00%
150.00
0.00
-100.00%
350.00
Repayment Of Debt
-4.93
-88.74%
-2.61
-114.46%
-1.22
-102.50%
-0.60
Long Term Debt Issuance
0.00
-100.00%
150.00
0.00
-100.00%
350.00
Long Term Debt Payments
-4.93
-88.74%
-2.61
-114.46%
-1.22
-102.50%
-0.60
Net Long Term Debt Issuance
-4.93
-103.34%
147.39
+12210.93%
-1.22
-100.35%
349.40
Net Common Stock Issuance
823.28
-24.06%
1,084.12
+611.02%
152.47
-47.81%
292.15
Proceeds From Stock Option Exercised
135.72
+19.85%
113.24
+515.48%
18.40
-5.67%
19.50
Net Other Financing Charges
—
-3.74
-206.81%
-1.22
-100.92%
132.22
Changes In Cash
-45.52
-161.54%
73.96
+112.51%
-591.41
-265.08%
358.25
Effect Of Exchange Rate Changes
0.93
+171.23%
-1.31
-422.80%
-0.25
+74.90%
-1.00
Beginning Cash Position
555.03
+15.06%
482.37
-55.09%
1,074.04
+49.84%
716.78
End Cash Position
510.44
-8.03%
555.03
+15.06%
482.37
-55.09%
1,074.04
Free Cash Flow
-967.58
-37.09%
-705.80
-28.44%
-549.53
-33.93%
-410.32
Interest Paid Supplemental Data
55.35
+36.45%
40.57
+13.36%
35.79
+252.34%
10.16
Income Tax Paid Supplemental Data
4.14
+65.71%
2.50
+27.83%
1.96
+13.86%
1.72
Amortization Of Securities
-38.35
-100.15%
-19.16
-104.20%
-9.38
0.00
Common Stock Issuance
823.28
-24.06%
1,084.12
+611.02%
152.47
-47.81%
292.15
Issuance Of Capital Stock
823.28
-24.06%
1,084.12
+611.02%
152.47
-47.81%
292.15
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category